文献速递贫血与红细胞疾病

新诊断输血依赖型地中海贫血幼儿早期起始去铁酮铁螯合治疗的安全性与有效性:一项随机对照试验

Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial.
PubMed 文献 · Am J Hematol · 2017-11-27

该随机对照试验纳入64例新诊断输血依赖型地中海贫血婴儿(年龄10至18个月,中位12个月,54.7%为男性,接受≤6次输血,血清铁蛋白>400至<1000 ng/mL),比较早期起始低剂量去铁酮(50 mg/kg/天)与延迟螯合治疗。结果显示,至随机化后约6个月,延迟组100%受试者血清铁蛋白>1000 µg/L且转铁蛋白饱和度>70%,而早期组无一例达到;早期组达到血清铁蛋白>1000 µg/L的时间延迟6个月(P<0.001),且未出现非预期、严重或重度不良事件。

要点

  • 早期起始低剂量去铁酮(50 mg/kg/天)可延迟输血依赖型地中海贫血幼儿血清铁蛋白>1000 µg/L的时间达6个月(P<0.001)。
  • 至随机化后约6个月,延迟组100%受试者血清铁蛋白>1000 µg/L且转铁蛋白饱和度>70%,早期组无一例。
  • 早期组未出现非预期、严重或重度不良事件。

核心结论

  • 在新诊断输血依赖型地中海贫血幼儿中,早期起始低剂量去铁酮可延迟转铁蛋白饱和度升高和血清铁蛋白>1000 µg/L,且未出现非预期、严重或重度不良事件。

研究设计与样本

  • 随机对照试验,纳入64例新诊断输血依赖型地中海贫血婴儿,年龄10至18个月(中位12个月),54.7%为男性,接受≤6次输血,血清铁蛋白>400至<1000 ng/mL,随机分为早期起始去铁酮组(低剂量50 mg/kg/天)和延迟螯合治疗组,随访至血清铁蛋白≥1000 µg/L,61例继续研究。

主要发现

  • 至随机化后约6个月,延迟螯合治疗组100%受试者达到血清铁蛋白>1000 µg/L且转铁蛋白饱和度>70%,而早期起始去铁酮组无一例达到。
  • 不稳定血浆铁>0.6 µM在延迟螯合治疗组和早期起始去铁酮组的发生率分别为97%和40%(P<0.001)。
  • 早期起始去铁酮组达到血清铁蛋白>1000 µg/L的时间延迟6个月(P<0.001),且未增加去铁酮剂量。
  • 早期起始去铁酮组未出现非预期、严重或重度不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Iron overload is inevitable in patients who are transfusion dependent. In young children with transfusion-dependent thalassemia (TDT), current practice is to delay the start of iron chelation therapy due to concerns over toxicities, which have been observed when deferoxamine was started too early. However, doing so may increase the risk of iron accumulation that will be manifested as toxicities later in life. This study investigated whether deferiprone, a chelator with a lower affinity for iron than deferoxamine, could postpone transfusional iron overload while maintaining a good safety profile. Recently diagnosed TDT infants (N = 64 their age ranged from 10 to 18 (median 12) months, 54.7% males; receiving ≤6 transfusions; serum ferittin (SF) >400 to < 1000 ng/mL were randomized to "early start deferiprone" (.ES-DFP) at a low dose (50 mg/kg/day) or to "delay chelation" (DC), and remained in the study until their serum ferritin (SF) level reached ≥1000 μg/L. 61 patients continued the study Levels of transferrin saturation (TSAT) and labile plasma iron (LPI) were measured as well. By approximately 6 months postrandomization, 100% of the subjects in DC group had achieved SF > 1000 µg/L and TSAT > 70% compared with none in the ES-DFP group. LPI level > 0.6 µM was observed in 97% vs. 40% of the DS and ES groups, respectively, (P < 0.001). The time to reach SF > 1000 µg/L was delayed by 6 months in the ES-DFP group (P < 0.001) without escalating DFP dose. No unexpected, serious, or severe adverse events were seen in the ES-DFP group.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Elalfy MS, Adly A, Awad H, et al. Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial. Am J Hematol. 2017. PMID: 29119631. doi:10.1002/ajh.24966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。